Abstract
Background-The utility of cytomegalovirus (CMV) urine cultures was checked in patients with HIV (a) to identify those at risk for CMV retinitis and (b) to guide clinical decisions on treatment and prophylaxis of CMV retinitis. Methods-HIV infected patients were tested for CMVuria by shell vial cell cultures. The prevalence of CMVuria was related to CD4 count, HIV risk group, and time before and after diagnosis of CMV retinitis Results-A total of 639 shell vial cell cultures were obtained from 266 HIV infected ophthalmic patients. Only 4% of all patients with a CD4 count >400x10'Il shed CMV in their urine compared with 42% with a CD4 count <50x10'I. Twenty three of25 patients with CMV retinitis had a CD4 count <50xl0Ol. Among 130 patients with a CD4 count <50x10'/l (a) those who were CMVuric had a nearly sevenfold risk (p<0.0001) of developing CMV retinitis (35%) compared with those who did not shed CMV in their urine (5%), and (b) CMVuria and CMV retinitis were more frequent in homosexuals (580/o125%) than in intravenous drug users (230/6115%). More than 1 year before diagnosis of CMV retinitis 18% of patients were CMVuric compared with 83% of patients who were CMV culture positive in the last 3 months. CMVuria under virustatic maintenance (when regular CMV testing was established), valence of CMVuria (2) fundus control within a short time s as a function of the (CMVuria was tested usually every 3 months), nous drug users and and (3) inability of outpatients to produce -ount <50x106/l, and urine on that particular occasion. r retinitis before and The prevalence of CMVuria for different itis.
CD4 classes in patients not treated for CMV ir urine tested more infection is shown in Figure 1 (266 patients, of CMV. while they 525 urine cultures). All patients with a CD4 class (Fig 1, table 2 ) count >600X106/1 tested negative. Only 4% of l (Fig 2) . In order to all patients with a CD4 count >400x1 06/1 shed )rtion of results by CMV in the urine compared with 21% of all ngle patients a class patients with a CD4 count from 400 to d as the mean of all 101x106/l There is, however, no great differ-;itive cultures in that ence among patients with a CD4 count from erval.
100 to 51x106/l and <50x106/l with 41% and nine cultures were 42%, respectively, being positive for CMV in s with a CD4 count urine culture. (see Fig 1, The prevalence of CMVuria and CMV retinitis in patients with a CD4 count <50x106/l is shown in Table 2 . The rate of retinitis was 18% in these patients with a higher but not significantly different percentage in homosexuals (25%) than in intravenous drug users (15%). CMVuria, on the other hand, was more frequent (p<0.001) in homosexuals (58%) than in intravenous drug users (23%). Interestingly only two of 25 patients with CMV retinitis had a CD4 count >50x106/l and 21 had CMVuria. Among all patients with a CD4 count <50x106/l those with CMVuria have a nearly sevenfold risk for CMV retinitis (19/54 = 35%) compared with patients with a CD4 count <50x106/l without CMVuria (4/76 = 5%, p<O.000l). Among the subgroups of homo- In two of these three patients the occurrence of CMVuria was associated with progression of retinitis under maintenance therapy with ganciclovir (Table 3) . They received the reinduction dose whereafter retinitis stabilised again and CMV was eliminated from the urine.
Discussion LIMITATIONS OF THE STUDY
Apart from the fact that our group of HIV patients is small in comparison with larger centres some other limitations of our study need to be discussed. Since our investigation is retrospective in nature there is no close monitoring of HIV patients for CMVuria. Thus, 208 examinations could not be related to a culture result while 639 urine cultures could be included in our study. There are, however, fewer than 10% of patients (28/294) without even one urine examination for CMV in the study period.
Selection bias probably plays no major role for inpatients as they were nearly all examined ophthalmically. There We feel that even this is a rather low threshold prompting many unnecessary visits of AIDS patients to the ophthalmologist. Indeed, 92% of our patients with CMV retinitis had CD4 counts <50x106/l which confirms the findings of others" 16 that these patients are at particular risk. However, in our study only every fifth patient had a CMV retinitis (every fourth in a homosexual population), if one only takes into account the very low CD4 count of <50x106/1. Also we saw no patient with CMV retinitis having a CD4 count >200x106/1 as has been reported.'7 Based upon our data, we believe one should not rely only on the CD4 count as single indicator for screening.
CMVURIA AS AN INDICATOR FOR THE RISK OF CMV

RETINITIS
In our study 83% of AIDS patients with CMV retinitis shed CMV in their urine during the last 3 months before diagnosis of retinitis. These data are similar to those of Zurlo et al6 who even found 19/19 patients to have positive urine cultures during the 7 days before diagnosis of retinitis. In our series CMV retinitis occurred in 35% of all patients with both a CD4 count <50x106/l and CMVuria, indicating a nearly sevenfold risk of patients with CMVuria developing CMV retinitis in comparison with those without CMVuria.
If primary prophylaxis with oral ganciclovir is considered at all for HIV patients" it seems worth while mainly to address the high risk group with a CD4 count <50x106/l and additional CMVuria. If we had screened only these patients, in 19 of 25 cases (76%) CMV retinitis would have been diagnosed early. Of the six remaining cases two had higher CD4 counts and four were not CMV positive in the urine. Interestingly, these latter four patients had a more benign course of retinitis with no loss of central vision and no involvement of an eye which was primarily free of retinitis (3/8 At present a study is under way in our clinic comparing the usefulness of CMV-PCR, the CMV pp65 antigen test in blood, and CMVuria for ophthalmological screening. But as long as none of the tests available has proved yet to be a better predictor of retinitis we will continue to use the urine culture for the reasons mentioned above. Holding to this concept ophthalmologists may not need primary chemoprophylaxis for CMV retinitis.
